RT Journal
A1 Singh S, Segal JB
T1 Thiazolidinediones and macular edema: Comment on “association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes”
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD July 9
VO 172
IS 13
SP 1011
OP 1013
DO 10.1001/archinternmed.2012.2461
UL http://dx.doi.org/10.1001/archinternmed.2012.2461
AB 
The thiazolidinediones, rosiglitazone and pioglitazone, are peroxisome proliferator–activated receptor γ (PPAR-γ) agonists. They effectively reduce glycated hemoglobin among patients with type 2 diabetes mellitus by approximately 1 to 1.5 percentage points compared with placebo and are used as second-line treatment agents. However, rosiglitazone and pioglitazone have been associated with peripheral edema, congestive heart failure, and bone fractures.1- 2 An increased risk of myocardial ischemia has been attributed to rosiglitazone.2 An increased risk of bladder cancer associated with pioglitazone is noted in the current label. Spontaneous reports of macular edema with the use of thiazolidinediones has resulted in regulatory warnings on this potential association. However, the causality remains unclear.